A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction

Trial Profile

A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs CSL 112 (Primary)
  • Indications Myocardial infarction
  • Focus Adverse reactions
  • Acronyms AEGIS-I
  • Sponsors CSL Behring
  • Most Recent Events

    • 16 Nov 2016 According to CSL Behring media release, results were presented today at the American Heart Association Scientific Sessions.
    • 16 Nov 2016 Primary endpoint has been met. (Clinically important change in renal status)
    • 16 Nov 2016 Primary endpoint has been met. (Clinically important change in drug-induced liver injury)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top